Goldman Sachs Group Inc Achilles Therapeutics PLC Transaction History

Goldman Sachs Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$2.26 - $3.38 $185 - $277	-82 Reduced 0.62%	13,247 $30,000
Q3 2022 Nov 10, 2022	SELL	$2.26 - $3.38 $185 - $277	-82 Reduced 0.62%	13,247 $0
Q2 2022 May 14, 2024	BUY	$1.96 - $3.04 $26,124 - $40,520	13,329 New	13,329 $34,000
Q2 2022 Aug 15, 2022	SELL	$1.96 - $3.04 $1,803 - $2,796	-920 Reduced 6.46%	13,329 $34,000
Q1 2022 May 16, 2022	BUY	$2.8 - $5.23 $3,497 - $6,532	1,249 Added 9.61%	14,249 $42,000
Q4 2021 Feb 14, 2022	BUY	$4.22 - $8.86 $54,860 - $115,179	13,000 New	13,000 $65,000

24.3M

Ticker ACHL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,774,000
Market Cap $47.3M
Description
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.